Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:57 2024-04-25 am EDT			5-day change	1st Jan Change
90 ^CHF	+0.99%		+6.48%	+6.04%

Apr. 24	BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating	MT
Apr. 24	Novartis Says New Malaria Drug Formulation Safe and Effective for Babies	MT

NOVARTIS AG : Goldman Sachs remains its Buy rating

July 22, 2021 at 02:38 am EDT

Keyur Parekh from Goldman Sachs retains his positive opinion on the stock with a Buy rating. Previously set at CHF 110, the target price has been slightly modified to CHF 111.

Latest news about Novartis AG

BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating	Apr. 24	MT
Novartis Says New Malaria Drug Formulation Safe and Effective for Babies	Apr. 24	MT
Dpa-AFX Overview: COMPANIES from 24.04.2024 - 15:15	Apr. 24	DP
NOVARTIS AG : UBS reaffirms its Buy rating	Apr. 24	ZD
NOVARTIS AG : Deutsche Bank gives a Buy rating	Apr. 24	ZD
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	Apr. 24	RE
Novartis: positive data for malaria treatment	Apr. 24	CF
NOVARTIS AG : JP Morgan remains Neutral	Apr. 24	ZD
Novartis, Medicines for Malaria Say Treatment for Babies Shows Efficacy	Apr. 24	DJ
Novartis Partnership Says New Malaria Drug for Babies Effective, Safe in Phase 2/3 Trial	Apr. 24	MT
Novartis Faces Lawsuit for Illegal Promotion of Asthma Drug as Preterm Labor Treatment	Apr. 24	MT
Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies	Apr. 24	CI
Novartis Receives FDA Approval for Gastroenteropancreatic Tumor Treatment in Pediatric Patients	Apr. 23	MT
US Equity Markets Close Higher Tuesday	Apr. 23	MT
Novartis Wins FDA Approval of Pancreatic Tumor Therapy in Children	Apr. 23	MT
Novartis Gets FDA Approval for Lutathera in Pediatric Treatment	Apr. 23	DJ
Novartis radioligand therapy Lutathera(R) FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors	Apr. 23	DJ
NOVARTIS : 2024 has started on a strong note; guidance upgraded	Apr. 23
Top Midday Stories: Shares of GE, Novartis, Danaher and Philip Morris Up Post-Earnings; Pepsi Stock Down Post-Earnings; Apple iPhone China Sales Drop 19%; Trump Poised for Windfall From Media Company Stock	Apr. 23	MT
Novartis’ Bumper Q1 Earnings Nudge Swiss Stocks Higher	Apr. 23	MT
Global markets live: Bayer, PepsiCo, Halliburton, Spotify, Apple...	Apr. 23
Corporate results bound the become the next catalyst for markets	Apr. 23
Dpa-AFX Overview: COMPANIES from 23.04.2024 - 15:15	Apr. 23	DP
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Apr. 23	MT
Trending : Novartis Shares Climb on Guidance Lift	Apr. 23	DJ

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Sector

Pharmaceuticals

Calendar

2024-05-22 - Deutsche Bank dbAccess European Champions Conference

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : 2024 has started on a strong note; guidance upgraded

April 23, 2024 at 01:24 pm EDT

Vas Narasimhan, CEO of Novartis: 40% margin by 2027

April 23, 2024 at 07:18 am EDT

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am EDT

More Strategies

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

97.51 USD

Average target price

108.2 USD

Spread / Average Target

+11.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+6.04%	199B
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.56%	358B
MERCK & CO., INC.	+19.26%	322B
ABBVIE INC.	+8.05%	297B
ASTRAZENECA PLC	+13.45%	219B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-11.67%	149B
AMGEN INC.	-6.80%	146B
SANOFI	+2.07%	117B

Other Pharmaceuticals

Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

NOVARTIS AG : Goldman Sachs remains its Buy rating

Latest news about Novartis AG

Chart Novartis AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novartis AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals